Polar Asset Management Partners’s Sarepta Therapeutics SRPT Stock Holding History

Polar Asset Management Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,000	Closed	-$1.22M	–	720
2024 Q4	$1.22M	Sell	10,000 -2,700	-21%	-$331K	0.01%	413
2024 Q3	$1.59M	Sell	12,700 -1,700	-12%	-$235K	0.03%	367
2024 Q2	$2.28M	Buy	14,400 +3,900	+37%	+$501K	0.05%	303
2024 Q1	$1.36M	Sell	10,500 -29,500	-74%	-$3.61M	0.02%	404
2023 Q4	$3.86M	Buy	40,000 +15,700	+65%	+$1.51M	0.07%	260
2023 Q3	$2.95M	Buy	24,300 +14,000	+136%	+$1.58M	0.07%	323
2023 Q2	$1.18M	Buy	+10,300	New	+$1.33M	0.02%	496

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Polar Asset Management Partners's SRPT Position: Q1 2025 in Review

Polar Asset Management Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 10,000 shares — an estimated $1.22M sold.

Polar Asset Management Partners first reported a position in SRPT in Q2 2023 and held it in 7 quarters. The position peaked at $3.86M in Q4 2023. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Polar Asset Management Partners reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Polar Asset Management Partners sold 10,000 Sarepta Therapeutics shares in Q1 2025, an estimated $1.22M.
Polar Asset Management Partners first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 7 quarters.
Polar Asset Management Partners's Sarepta Therapeutics position peaked at $3.86M in Q4 2023.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Polar Asset Management Partners's 13F filing for Q1 2025, filed 15 May 2025.